艾拉莫德治疗类风湿关节炎的临床疗效观察

目的对风湿关节炎患者运用艾拉莫德进行治疗,分析其临床疗效,并探讨其对免疫学指标的影响。方法 90例活动期类风湿关节炎患者,分别给予50 mg/d的艾拉莫德片(甲组),25 mg/d的艾拉莫德片(乙组)及10毫克/周的甲氨蝶呤(丙组)。在6周及12周时,对三组临床疗效及免疫学指标进行观察与评估。结果甲乙丙三组在用药6周后ACR20开始上升,用药12周之后,在ACR20标准上,甲组为53.3%(16/30),乙组为36.7%(11/30),丙组为50%(15/30),甲组要优于乙组(P<0.05),甲组与丙组对比差异不显著,不具有统计学意义(P>0.05);三组的Ig A、Ig M以及Ig G等免疫学指标均明显改善,而甲乙两组的Ig A的改变要显著优于丙组(P<0.05)。结论作为一种慢作用药,艾拉莫德在治疗类风湿关节炎上的效果显著,此药物能够免疫调节B淋巴细胞,抑制免疫球蛋白产生。

Clinical Observation of Iguratimod Treat Rheumatoid Arthritis

Objective To study the efficacy of iguratimod in treating rheumatoid arthritis（RA） and analysis the change of immunological indexes. Methods Ninety patients with active RA were allocated to 3 groups：iguratimod 50 mg each day, 25 mg each day or 10 mg MTX each week. Clinical and laboratory parameters were analyzed on 6, 12 weeks. Results After 6 weeks, ACR20 started to rise. After 12 weeks, the ACR20 of the three groups were respectively： 50 mg/d dosage group was 53.3% （16/30）, 25 mg/d dosage group was 36.7% （11/30）, the control group was 50% （15/30）, ACR20 was significantly higher in 50 mg/d dosage group than in 25 mg/d dosage group（P〈0.05）, there was no significant difference between the 50 mg/d dosage group and the control group（P〉0.05）; IgA, IgM and IgG of three groups all improved, and IgA of 50 mg/d dosage group and 25 mg/d dosage group were more significantly improved compared with the control group （P〈0.05）. Conclusion Iguratimod i8 effective in the treatment of rheumatoid arthritis and it can inhibit the produce of immunoglobulin.